ANTICANCER ACTIVITY OF SUNITINIB ANALOGUES IN BRAIN CANCER MODELS

Girstautė Dabkevičiūtė1, Elias Maccioni2, Vilma Petrikaitė1

1 Department of Drug Targets Histopathology, Institute of Cardiology, Lithuanian University of Health Sciences, Lithuania

2 Department of Life and Environmental Sciences, Cagliari University, Italy

Glioblastoma (GBM) is the most aggressive type of brain cancer. Median survival time for GBM patients is about 12.1 to 14.6 month [1], and there are still extremely limited opportunities of conventional therapy. Tyrosine kinase inhibitors currently are considered as perspective targeted therapy for GBM. There are numerous studies linking changes in kinase activity to carcinogenesis and tumour progression. Tyrosine kinase inhibitors generally target the active site of the kinase and thereby prevent the phosphorylation resulting in inhibition of migration and apoptosis of cancer cells [2]. One of them is sunitinib, a multi-targeted agent, approved for the treatment of kidney cancer and gastrointestinal stromal tumours [3]. Moreover, the new chemical compounds are suggested as more effective sunitinib analogues [4]. The aim of our study was to evaluate the effect of new sunitinib analogues on human brain cancer cell viability and migration.

The two human GBM cell lines, U87-MG and A172, and non-malignant cell line – human fibroblasts were used to investigate cytotoxic effect of 16 sunitinib analogues in vitro. The effect of kinase inhibitors on cell viability was evaluated by MTT assay after 72 hours of incubation, and the most active kinase inhibitors that reduced cell viability up to 5% or less were selected. Then the EC50 values of the most active compounds were established and compared to the sunitinib activity. Single cell migration assay was performed to examine the effect of selected compounds on U87-MG and A172 cell migration. Cells were seeded in the dishes with numbered grids. Photos were taken of cells every hour up to 8 hours. Then coordinates of each cell were calculated. The single cell distance travelled per hour was determined and defined as cell velocity. The data are presented as average cell velocity ± standard deviation

The results of MTT assay have shown that compounds 1, 6 and 7 were the most active ones. All three tested compounds more efficiently reduced brain cancer cell viability of A172 cell line than U87-MG cell line, also non-malignant cell viability. It should be noted that compound 6 was the only one that had stronger cytotoxic effect on both cancer cell lines in comparison with non-malignant cells. However, compound 1 had the greatest effect on cell viability (EC50 values on U87-MG, A172 and HF were 82 ± 6 nM, 72 ± 6 nM and 82 ± 6 nM, respectively). Compounds 6 and 7 reduced 50% of cell viability at range of concentrations from 112 to 397 nM. All tested sunitinib analogues were more active than sunitinib. Regarding migration assay in U87-MG cell line, compound 1 was 16% more effective than sunitinib and decreased average cell velocity by 2.5 times compared to the control. Compounds 6 and 7 decreased average cell velocity by 55% and 48%, respectively, compared to the control. In A172 cell line, compounds 6 and 7 had the greatest effect on cell migration as cell velocity was reduced by 51% and 60%, respectively, compared to the control.

To conclude, compound 6 may be worthy of further studies as it had U87-MG and A172 cancer cell specific cytotoxicity as well as was effective kinase inhibitor in both cell lines.


[1] Bahadur, S., Sahu, A. K., Baghel, P. & Saha, S. Oncol Rev. 13, (2019).

[2] Pottier C, Fresnais M, Gilon M, et al. Cancers. 2020 Mar;12(3):731.

[3] Le Tourneau C, Raymond E, Faivre S. Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST). Ther Clin Risk Manag. 2007 Jun;3(2):341–8.

[4] Meleddu R, Petrikaite V, Distinto S, Arridu A, Angius R, Serusi L, et al. Investigating the Anticancer Activity of Isatin/Dihydropyrazole Hybrids. ACS Med Chem Lett. 2019 Apr 11;10(4):571–6.